Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHBP | P24387 | 3/20 | 0.58 |
| ▸ | CRHR2 | Q13324 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | NAMPT | P43490 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10133618 | 1.00 | CRHBP (0.58) | CRHBPCRHR2KMT2ANAMPTHPGD | |
| SCHEMBL10116643 | 0.90 | RXFP1 (0.56) | CRHBPCRHR2KMT2ANAMPTHPGD | |
| SCHEMBL10133619 | 0.90 | RXFP1 (0.56) | CRHBPCRHR2KMT2ANAMPTHPGD | |
| SCHEMBL10114527 | 0.87 | MAPT (0.52) | KMT2AALDH1A1NPC1THRBMEN1 | |
| SCHEMBL10133455 | 0.87 | MAPT (0.52) | KMT2AALDH1A1NPC1THRBMEN1 | |
| SCHEMBL10116505 | 0.87 | MAPT (0.52) | KMT2AALDH1A1NPC1THRBMEN1 | |
| SCHEMBL10116508 | 0.85 | THRB (0.65) | KMT2AHPGDALDH1A1THRBMEN1 | |
| SCHEMBL10133287 | 0.85 | THRB (0.65) | KMT2AHPGDALDH1A1THRBMEN1 | |
| SCHEMBL10116361 | 0.84 | CRHBP (0.64) | CRHBPCRHR2KMT2ANAMPTHPGD | |
| SCHEMBL10134535 | 0.84 | CRHBP (0.64) | CRHBPCRHR2KMT2ANAMPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8115027-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2012-02-14 | — | — | US | disclosed |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2010-11-18 | — | — | US | disclosed |
| US-7781461-B2 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2010-08-24 | — | — | US | disclosed |
| US-7265130-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2007-09-04 | — | — | US | disclosed |
| US-20070015762-A1 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2007-01-18 | — | — | US | disclosed |
| US-20070015762-A1 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015762-A1 | NPY Y5 antagonist | NPY5R, NPY1R, NPY2R | CRHBP 238/4885CRHR2 12/4885KMT2A 2912/4885 |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | NPY5R, NPY1R, NPY2R | CRHBP 256/4885CRHR2 13/4885KMT2A 2768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.